Tempus Expands Data and Sequencing Collaboration with Remix Therapeutics

Tempus AI, Inc. (NASDAQ: TEM), a prominent figure in artificial intelligence and precision medicine, has announced an enhanced collaboration with Remix Therapeutics, a biotechnology firm focused on developing small molecule therapies targeting RNA processing to combat disease drivers. Originally, the collaboration began with the licensing of specific, de-identified data cohorts and has now evolved into a more comprehensive strategic partnership.

Remix Therapeutics is utilizing Tempus’ extensive multimodal data to analyze specific patient groups, such as those with Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML), through Tempus’ advanced data analytics platform, Lens. The expanded collaboration will also provide next-generation sequencing support for Remix’s Phase I trial of REM-422, a potent, selective, and oral small molecule messenger RNA (mRNA) degrader developed by Remix.

To further its research, Remix employs Tempus’ xT and xR assays for comprehensive DNA and RNA data capture. Additionally, Tempus’ xM Monitor, a circulating tumor DNA (ctDNA) assay, is used on an exploratory research basis to track treatment responses. The xM Monitor detects and monitors changes in circulating tumor fractions, helping to evaluate therapy responses in patients with advanced cancers.

Ryan Fukushima, Chief Operating Officer of Tempus, expressed enthusiasm for the partnership, stating, "We’re thrilled to collaborate with a biotech company like Remix that recognizes the value that Tempus’ multimodal data brings to their critical work. Our swift expansion of this collaboration allows us to provide Remix with a range of our offerings uniquely designed to support their research and development objectives."

Dominic Reynolds, Ph.D., Chief Scientific Officer of Remix, echoed this sentiment, emphasizing the crucial role of Tempus’ resources in advancing their lead candidate, REM-422. "Tempus’ multimodal data, analytics, and sequencing support are invaluable as we move REM-422 into clinical stages. This collaboration equips us with robust tools and data to propel our research, ultimately driving us closer to creating impactful new treatments for patients."

Tempus is a technology company that enhances precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data and an operating system designed to make that data accessible and useful, Tempus offers AI-enabled precision medicine solutions. These solutions help physicians deliver personalized patient care while also facilitating the discovery, development, and delivery of optimal therapeutics. Tempus aims to ensure that each patient benefits from the treatments of previous patients by providing tools that learn and improve as more data is collected.

The collaboration between Tempus and Remix Therapeutics represents a significant step forward in the intersection of artificial intelligence, data analytics, and biotechnology. By leveraging Tempus’ advanced data platforms and assays, Remix is well-positioned to advance its innovative treatments and potentially provide new hope for patients with challenging conditions such as ACC and AML.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!